LKC Technologies Announces Acquisition by AMETEK
LKC Technologies, a leader in functional retinal testing using electroretinography (ERG), announces that it has been acquired by AMETEK, Inc., a global provider of industrial technology solutions.
Expanding ERG in Diabetic Eye Care
Handheld ERG provides early functional insights in diabetic retinopathy and integrates seamlessly into clinic workflow. Recent evidence shows the RETeval DR Score is the strongest predictor of progression to vision-threatening complications, enabling more proactive, personalized care.
PolyActiva and RareSight Join Forces to Target Rare Pediatric Retinal Diseases
As PolyActiva and RareSight team up to develop sustained-release therapies for rare pediatric IRDs, the RETeval ERG stands out as an essential tool that enables easy, noninvasive functional assessment of retinal and optic nerve disease in children.
Handheld RETeval device outshines other metrics for predicting DR complications
Could a single number help predict vision-threatening diabetic retinopathy? New research from Ophthalmology Science finds the RETeval DR Score outperformed other metrics in predicting progression to vision-threatening complications.
AAOpt 2025: Diabetes case studies with an eye to the future with Dr Paul Chous
How can optometrists leverage new technologies to improve early detection, monitoring, and management of diabetic eye conditions? This question and more concerning the care for patients with diabetes were tackled by Paul Chous and Julie Rodman.
A Tale of Two Patients: How ERG Uncovered Hidden Diabetic Retinopathy Differences
When two patients present with similar-looking retinas, does that mean they require the same care? Optometrist Kelly MacDonald would have thought so, if not for the RETeval’s DR Score.
Beyond ETDRS DRSS: Additional Tests Improve Early Detection of Diabetic Retinopathy
Diabetic retinopathy, the leading cause of blindness globally, is currently detected via the ETDRS diabetic retinopathy severity scale (DRSS). While effective, there are now new ways to screen, including some that may detect signs of diabetic retinopathy earlier than the DRSS.
What to Do When Fields and OCT are Inconclusive: A Case Report
Glaucoma suspects often present a challenge. When a patient with existing DR was referred for suspected glaucoma, optometrist Mike Cymbor began with visual fields, OCT, and OCT-A. When those tests failed to provide conclusive results, Dr. Cymbor reached for his RETeval handheld ERG.
Study: Functional Testing Outperforms Structural Imaging in Predicting DR Progression
A prospective trial shows that ERG and pupillometry more accurately forecast progression to vision-threatening diabetic retinopathy.
Study: ERG outperforms structural testing for DR risk assessment
New research published in Ophthalmology Science evaluated the use of ERG compared to three forms of structural testing in identifying diabetic retinopathy patients at the highest risk for developing vision-threatening complications.
Study Identifies RETeval DR Score as the Strongest Predictor of DR Progression
This study from Ophthalmology Science found the RETeval DR Score to be the strongest predictor of progression to vision-threatening DR – outperforming OCTA, UWF-FA, and fundus photography.
Beyond BCVA: How to Improve Your Visual Function Evaluation in DR Patients
Dr. Sarah Gleason emphasizes the importance of evaluating functional vision, not just structural changes, in patients with diabetic retinopathy. It explores a wide range of tests, including ERG, highlighting how these tools can detect visual impairment earlier and guide more comprehensive care.
Warning: This product can expose you to chemicals including lead, which is known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to